Sugi Predict

Sugi Predict / Compounds / SCHEMBL38049

SCHEMBL38049

SCHEMBL38049

O=C(O)/C=C/C1CCCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ TSHR P16473 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ EGLN3 Q9H6Z9 1/20 0.40
▸ POLB P06746 1/20 0.38
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ UGT2B7 P16662 2/20 0.35
▸ PADI4 Q9UM07 2/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38050 1.00 HTT (0.43) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL4257649 1.00 HTT (0.43) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL17263955 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL1151110 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL221714 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL23749603 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL9743609 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL4599663 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL15290579 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR
SCHEMBL9063561 0.97 HTT (0.47) HTTSMN1; SMN2NPC1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117986702-A Preparation method of carboxyl polysulfide modified rubber composite material 沈阳化工大学 2024-05-07 — — CN claimed
CN-119528911-A Reu Ke Tie preparation method of nylon 南通常佑药业科技有限公司 2025-02-28 — — CN disclosed
CN-119032095-A Improved process for preparing ruxolitinib 印度颗粒有限公司 2024-11-26 — — CN disclosed
US-20240308931-A1 LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS THE SCRIPPS RESEARCH INSTITUTE 2024-09-19 — — US disclosed
EP-4370490-A1 LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS The Scripps Research Institute (US) 2024-05-22 — — EP disclosed
CN-117986702-A Preparation method of carboxyl polysulfide modified rubber composite material 沈阳化工大学 2024-05-07 — — CN disclosed
WO-2024042448-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB GRANULES INDIA LIMITED (IN) 2024-02-29 — — WO disclosed
CN-117327010-A Preparation method of 3-tertiary butyl amino acrylamide derivative 常州大学 2024-01-02 — — CN disclosed
EP-3838903-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR INCYTE HOLDINGS CORP (US) 2023-11-22 — — EP disclosed
EP-3838903-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR INCYTE HOLDINGS CORP (US) 2023-11-22 — — EP disclosed
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer INCYTE CORPORATION 2007-06-14 — — US disclosed
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer INCYTE CORPORATION 2007-06-14 — — US disclosed
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer INCYTE CORPORATION 2007-06-14 — — US disclosed
US-7030262-B2 3-Amino-2-hydroxyalkanoic acids and their prodrugs ABBOTT LABORATORIES (US) 2006-04-18 — — US disclosed
EP-1546087-A1 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS Abbott Laboratories (US) 2005-06-29 — — EP disclosed
US-20040122098-A1 3-Amino-2-hydroxyalkanoic acids and their prodrugs ABBVIE INC. 2004-06-24 — — US disclosed
WO-2004013085-A1 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS ABBOTT LABORATORIES (US) 2004-02-12 — — WO disclosed
EP-0846689-B1 Benzimidazole compounds PFIZER (US) 2004-01-14 — — EP disclosed
EP-0846689-A1 Benzimidazole compounds PFIZER INC. (US) 1998-06-10 — — EP disclosed
US-3975429-A Cyclopropanemethyl esters of cinnamic acid and derivatives thereof ZOECON CORPORATION (US) 1976-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308931-A1 LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS PPARD, PPARA, PDCD1LG2 HTT 3977/4885SMN1; SMN2 3416/4885NPC1 3920/4885
US-20040122098-A1 3-Amino-2-hydroxyalkanoic acids and their prodrugs HDGF, HCAR2, HCAR3 HTT 3905/4885SMN1; SMN2 4281/4885NPC1 936/4885
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer JAK1, JAK3, MAP3K4 HTT 3263/4885SMN1; SMN2 3882/4885NPC1 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.